Vivosense is pleased to announce that Ieuan Clay has joined the company as Director of Science. He brings extensive knowledge in developing and validating novel digital measures gained across experiences in industry, healthtech and academia.
“I’m excited at this opportunity to combine my experience in developing new sources of evidence with my passion for patient-centricity. Vivosense has a compelling vision for how digital measures can deliver value for patients and sponsors alike,” said Clay. “What we are building will change the landscape of what is currently possible.”
Vivosense recently completed a $25 Million Series A financing round co-led by the Perceptive Xontogeny Venture (PXV) Fund and Switzerland-based Debiopharm Innovation Fund. They’ll use the financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital COAs for life science research.
“Ieuan’s knowledge and experience in developing digital measures will enhance VivoSense’s Scientific approach to providing meaningful outcome measures that are valued and trusted. We are delighted to add his leadership and expertise to our team, showcasing our commitment to delivering validated endpoints in clinical trials and health care.” Dudley Tabakin, CEO of VivoSense.
Before joining Vivosense, Ieuan Clay initiated and led the Digital Endpoints group within Novartis Research, implementing new digital measures into clinical trials and advancing the qualification of real-world gait speed with the European Medicines Agency (EMA). At Evidation Health, he helped design and build the Heart Health on Achievement health programs in collaboration with the American College of Cardiology. He served as Chief Scientific Officer for the Digital Medicine (DiMe) society, responsible for scientific strategy and output.
He lectures at Eidgenössische Technische Hochschule Zürich (ETHZ) and Fachhochschule Nordwestschweiz (FHNW) in Digital Health, is an Editorial Board Member at Karger Digital Biomarkers, and serves on the Scientific Advisory Board of IMI IDEA FAST. He earned a PhD degree from the University of Cambridge, focusing on new technologies and data analytics.
“There are so many patients waiting for outcomes that better describe their experience and so many decision-makers desperate for more tools to help them advance effective therapies,” Clay says. “I am thrilled to be part of the team here at Vivosense, which will drive the development and qualification of new evidence to address this gap.”
